Article Text

PDF

Antiplatelet Drugs in the Secondary Prevention of Stroke
  1. Cathie Sudlow1,
  2. Graeme Hankey2
  1. 1Department of Clinical Neurosciences, University of Edinburgh, Western General Hospital, Edinburgh, UK;
  2. 2Royal Perth Hospital, Western Australia and Department of Medicine, University of Western Australia, E-mail: gjhankey{at}cyllene.uwa.edu.au

    Abstract

    INTRODUCTION

    Stroke is a major cause of death and disability in developing and developed countries (Murray & Lopez 1996). Incidence rises steeply with age so that about three quarters of incident strokes occur in people over 65 years of age. In community-based studies among whites, around 80% of strokes are ischaemic, while 15% are due to primary intracerebral haemorrhage, and 5% to subarachnoid haemorrhage (Fig. 1). The proportion of haemorrhagic strokes in the mainly non-white populations of Asia and Africa may be somewhat higher, but ischaemic stroke is still the dominant problem (Sudlow & Warlow 1997).

    The management of patients with acute ischaemic stroke aims to restore tissue perfusion, minimize cytotoxic brain damage and cerebral oedema, prevent complications of stroke, and prevent a recurrent stroke or other serious vascular event.

    About 10% of patients with a first-ever acute ischaemic stroke die within 30 days of onset. Most of these early

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.